acitretin has been researched along with cyclosporine in 110 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (12.73) | 18.2507 |
| 2000's | 26 (23.64) | 29.6817 |
| 2010's | 56 (50.91) | 24.3611 |
| 2020's | 14 (12.73) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Detmar, M; Hettmannsperger, U; Kammler, HJ; Orfanos, CE; Owsianowski, M; Tenorio, S | 1 |
| Bjerke, JR; Degré, M; Gallati, H; Jablonska, S; Majewski, S; Matre, R; Tigalonova, M | 1 |
| Feldmann, R; Masgrau-Peya, E; Mesheit, J; Salomon, D; Saurat, JH | 1 |
| Burke, MD; Omar, G; Ormerod, AD; Shah, IA; Whiting, PH | 1 |
| Frappaz, A; Larbre, B; Nicolas, JF; Thivolet, J | 1 |
| Gambla, C; Koo, J; Nguyen, Q | 1 |
| Bjerring, P; Heickendorff, L; Zachariae, H | 1 |
| Altmeyer, P; Nüchel, C | 1 |
| Kuijpers, AL; van de Kerkhof, PC; van Dooren-Greebe, JV | 1 |
| de Rooij, MJ; van de Kerkhof, PC | 1 |
| Katz, HI | 1 |
| Bergman, R; Friedman-Birnbaum, R; Sprecher, E | 1 |
| Roenigk, HH | 1 |
| Koo, J | 1 |
| Koo, J; Liao, W | 1 |
| Feldman, S | 1 |
| Gordon, KB; McClure, SL; Valentine, J | 1 |
| van de Kerkhof, P | 1 |
| Agnew, KL; Bunker, CB | 1 |
| Kormeili, T; Lowe, NJ; Patnaik, R; Rizk, D; Yamauchi, PS | 1 |
| Lebwohl, M; Maryles, S; Rozenblit, M | 1 |
| Short, MW; Vaughan, TK | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T; Stern, RS | 1 |
| Evans, C; Feldman, SR; Russell, MW | 1 |
| Cather, JC; Menter, A | 1 |
| Haustein, UF; Paasch, U | 1 |
| Menon, K; Siu, K; Strober, BE | 1 |
| Usmani, N; Wilson, C | 1 |
| Gyulai, R; Kemény, L | 1 |
| Girard, C; Guilhou, JJ | 1 |
| Bos, JD; Bossuyt, PM; de Rie, MA; deBorgie, CA; Heydendael, VM; Opmeer, BC; Spuls, PI | 1 |
| Rebora, A | 1 |
| De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE | 1 |
| Elston, CM; O'Toole, EA; Webber, NK | 1 |
| Alegre de Miguel, V; Martínez Casimiro, L; Sánchez Carazo, JL | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
| Ahdout, J; Chiu, M; Mandel, H | 1 |
| Altieri, E; Baricordi, O; Borghi, A; Fogli, E; Melchiorri, L; Rizzo, R; Stignani, M; Virgili, A | 1 |
| Alomar, A; Barco, D; Puig, L; Vilarrasa, E | 1 |
| Di Lernia, V | 1 |
| O'Rielly, DD; Rahman, P | 1 |
| Lotti, T; Pescitelli, L; Prignano, F; Ricceri, F; Ruffo, G | 1 |
| Rallis, E; Verros, CD | 1 |
| Boulinguez, S | 1 |
| Cerri, A; Colombo, L; Crespi, E; Gualandri, L; Mapelli, ET; Marconi, M; Menni, S | 1 |
| Arcese, A; Camplone, G; Carlesimo, M; Di Russo, PP; Gamba, A; La Pietra, M; Mari, E; Orsini, D | 1 |
| Frambach, Y; Gerdes, S; Mössner, R; Philipp, S; Rotterdam, S; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Cohen, DE; Miller, K; Stein, JA; Wu, TP | 1 |
| Albarrán-Planelles, C; Báez-Perea, JM; González-Fernández, JA; Jiménez-Gallo, D; Linares-Barrios, M; Martínez-Rodríguez, A | 1 |
| Bagel, J; Blauvelt, A; Hsu, S; Hugh, J; Lebwohl, M; Nijhawan, RI; Van Voorhees, AS; Weinberg, JM | 1 |
| Burden, AD; Burfield, L | 1 |
| Alsina-Gibert, M; Belinchón, I; Carazo, C; Carrascosa, JM; Carretero, G; Dauden, E; De la Cueva-Dobao, P; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha Sebastián, F | 1 |
| Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C | 1 |
| Aractingi, S; Aubin, F; Barnetche, T; Beylot-Barry, M; Cantagrel, A; Joly, P; Jullien, D; Le Maitre, M; Misery, L; Ortonne, JP; Paul, C; Richard, MA; Rouzaud, M; Sevrain, M; Villani, AP | 1 |
| Akçali, C; Guven, EH; Guvenc, U; Inaloz, HS; Kirtak, N; Ozgoztasi, O | 1 |
| Errichetti, E; Patrone, P; Pegolo, E; Stinco, G | 1 |
| Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Linn, KA; Robertson, AD; Schleicher, SM; Shin, DB; Shinohara, RT; Sperber, BR; Stierstorfer, MB; Takeshita, J; Troxel, AB; Van Voorhees, AS; Wang, S; Weisman, JD | 1 |
| Kirby, B; Ryan, C | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Foulkes, AC; Warren, RB | 1 |
| Abeni, D; Giannantoni, P; Paradisi, A; Tabolli, S | 1 |
| Ara, M; Gracia, T; Pastushenko, E | 1 |
| Al-Ismail, D; Anderson, E; Batul Syed, S; Burden-Teh, E; Carmichael, A; Caruana, D; Darne, S; Dolman, S; Glover, M; Helbling, I; Hughes, B; Hughes, J; Jones, V; Jury, C; Kalavala, M; Katugampola, R; Lam, ML; McPherson, T; Moore, A; Murphy, R; Natarajan, S; Richards, L; Taibjee, SM; Taylor, A; Webster, S | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Weyergraf, AJ; Wilsmann-Theis, D | 1 |
| Bangsgaard, N; Rørbye, C; Skov, L | 1 |
| Armstrong, AW; Blauvelt, A; Krueger, GG | 1 |
| Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP | 1 |
| Arenberger, P; Bachelez, H; Barker, J; Dauden, E; de Jong, EM; Feist, E; Gisondi, P; Jacobs, A; Jobling, R; Kemény, L; Maccarone, M; Mrowietz, U; Nast, A; Ormerod, AD; Papp, KA; Paul, C; Reich, K; Rosumeck, S; Saiag, P; Smith, C; Spuls, PI; Talme, T; Thio, HB; van de Kerkhof, P; Werner, RN; Yawalkar, N | 1 |
| Bae, SH; Kim, SJ; Lee, JB; Lee, SC; Won, YH; Yun, SJ | 1 |
| Abasq, C; Aubin, F; Barbarot, S; Begon, E; Boralevi, F; Bourrat, E; Bursztejn, AC; Charbit, L; Chiaverini, C; Droitcourt, C; Hadj-Rabia, S; Lasek, A; Mahé, E; Mallet, S; Maruani, A; Mazereeuw-Hautier, J; Phan, A; Plantin, P; Souillet, AL | 1 |
| Gulliver, WP; van der Zee, HH | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Carpentieri, A; De Marco, IM; Loconsole, F; Loiacono, A; Pacello, L; Picconi, O | 1 |
| Alfageme Roldán, F; Bermejo Hernando, A; Calvo González, JL; Marqués Sánchez, P | 1 |
| Anliker, M; Boehncke, WH; Borradori, L; Conrad, C; French, LE; Gilliet, M; Häusermann, P; Itin, P; Kolios, AG; Laffitte, E; Mainetti, C; Navarini, AA; Yawalkar, N | 1 |
| Markham, T; O'Gorman, SM; Storan, ER | 1 |
| Alpsoy, E; Bulbul-Baskan, E; Ergun, T; Onsun, N; Salman, A; Saricam, MH; Sarioz, A; Seckin Gencosmanoglu, D | 1 |
| Cline, A; Feldman, SR; Smith, J | 1 |
| Arenberger, P; Cetkovska, P; Dolezal, T; Fialova, J; Gkalpakiotis, S; Jircikova, J; Kojanova, M | 1 |
| Barker, JN; Capon, F; Choon, SE; Lau, BW; Lim, DZ | 1 |
| Croney, S | 1 |
| Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P | 1 |
| Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ | 1 |
| Ashcroft, DM; Griffiths, CEM; Jabbar-Lopez, ZK; Kleyn, CE; Mason, KJ; McElhone, K; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Williams, S; Wilson, N; Yiu, ZZN | 1 |
| Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M | 1 |
| Carrascosa, JM; Daudén, E; Guisado, C; Puig, L; Sulleiro, S | 1 |
| Arnone, M; Bernardo, WM; Carvalho, AVE; Takahashí, MDF | 1 |
| Bulut, H; Engin, B; Gökalp, E; Kutlubay, Z; Özkoca, D; Serdaroğlu, S; Songür, A; Tanakol, A; Tüzün, Y; Vehid, HE | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Kromer, C; Lippert, U; Mössner, R; Schön, MP | 1 |
| Villani, AP | 1 |
| Chavan, D; Jamale, V; Kale, M; Nikam, B; Shah, S | 1 |
| Ahn, KJ; Cho, YA; Choe, YB; Hong, JR; Hong, JY; Jeong, H; Kim, H; Kim, SM; Lee, YW; Yang, HS | 1 |
| Chat, VS; Han, G; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| Aylı, M; Caliskan, E; Coban, SN; Esme, P; Ugur, B | 1 |
| Bahloul, E; Bougacha-Elleuch, N; Ennouri, M; Fakhfakh, F; Marrakchi, S; Sellami, K; Turki, H | 1 |
| Carrascosa, JM | 1 |
| Alabas, OA; Bewley, A; Griffiths, CEM; Hampton, PJ; Laws, PM; Lunt, M; Mason, KJ; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Yiu, ZZN | 1 |
| Jin, HZ; Wang, HM; Xu, JM | 1 |
40 review(s) available for acitretin and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in psoriasis therapy.
Topics: Absorption; Acitretin; Administration, Cutaneous; Calcitriol; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Ointments; Psoriasis | 1997 |
[Systemic therapy of psoriasis].
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Photochemotherapy; Phototherapy; Psoriasis | 1996 |
Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
Topics: Acitretin; Aged; Aged, 80 and over; Calcitriol; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Drug Combinations; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis | 1997 |
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Topics: Acitretin; Administration, Topical; Calcitriol; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Risk; Safety; Treatment Outcome | 1997 |
Acitretin combination therapy.
Topics: Acitretin; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Ultraviolet Therapy | 1999 |
Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results.
Topics: Acitretin; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 1999 |
Update on psoriasis therapy: a perspective from the USA.
Topics: Acitretin; Calcitriol; Clobetasol; Cyclosporine; Dermatologic Agents; Humans; Photochemotherapy; Psoriasis; United States | 2000 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Nicotinic Acids; Patient Education as Topic; Phototherapy; Psoriasis; PUVA Therapy; Quality of Life; Social Support; Triamcinolone | 2000 |
Comparative tolerability of systemic treatments for plaque-type psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Combinations; Eye Diseases; Humans; Keratolytic Agents; Liver Cirrhosis; Lymphoproliferative Disorders; Methotrexate; Nausea; Pancytopenia; Pneumonia; Pruritus; Psoriasis; PUVA Therapy; Skin Neoplasms | 2002 |
Vitamin D and systemic therapy.
Topics: Acitretin; Administration, Oral; Administration, Topical; Calcitriol; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Ointments; Psoriasis | 2002 |
Current systemic therapies for psoriasis: where are we now?
Topics: Acitretin; Antineoplastic Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Remission Induction | 2003 |
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
Topics: Acitretin; Cyclosporine; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2003 |
Combining traditional agents and biologics for the treatment of psoriasis.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins | 2005 |
Conventional systemic agents for psoriasis. A systematic review.
Topics: Acitretin; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxyurea; Immunosuppressive Agents; Methotrexate; Practice Guidelines as Topic; Psoriasis; Thioguanine; Treatment Outcome | 2006 |
[The immunology of psoriasis: from basic research to the bedside].
Topics: Acitretin; Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Biomedical Research; Cell Differentiation; Cell Proliferation; Cyclosporine; Dermatologic Agents; Humans; Immunity, Cellular; Immunosuppressive Agents; Infliximab; Keratinocytes; Keratolytic Agents; Methotrexate; Psoriasis; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Ultraviolet Therapy | 2006 |
[Psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Psoriatic; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; HIV Infections; Humans; Infant; Infant, Newborn; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Skin; Time Factors; Vitamins | 2006 |
[Long-term control of psoriasis is necessary].
Topics: Acitretin; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytokines; Dermatologic Agents; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Recurrence | 2008 |
Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.
Topics: Acitretin; Acrodermatitis; Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Clobetasol; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Mycophenolic Acid; Nails; Paronychia; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor Inhibitors | 2010 |
Pharmacogenetics of psoriasis.
Topics: Acitretin; Adrenal Cortex Hormones; Antibodies, Monoclonal; Cyclosporine; Genetic Predisposition to Disease; Humans; Methotrexate; Pharmacogenetics; Precision Medicine; Psoriasis | 2011 |
Facial follicular cysts: a case of lichen planus follicularis tumidus?
Topics: Acitretin; Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Cysts; Face; Female; Histamine Antagonists; Humans; Keratolytic Agents; Lichen Planus; Middle Aged; Skin | 2013 |
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Mycophenolic Acid; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
Psoriasis.
Topics: Acitretin; Administration, Topical; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Phototherapy; Psoriasis; Tumor Necrosis Factor-alpha | 2013 |
Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.
Topics: Acitretin; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Evidence-Based Medicine; Humans; Keratolytic Agents; Photochemotherapy; Practice Guidelines as Topic; Psoriasis | 2014 |
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Pharmacogenomics and the resulting impact on psoriasis therapies.
Topics: Acitretin; Cyclosporine; Cytokines; HLA-C Antigens; Humans; Immunosuppressive Agents; Inflammation; Keratolytic Agents; Methotrexate; Pharmacogenetics; Phototherapy; Polymorphism, Genetic; Precision Medicine; Psoriasis; Research Design; Tumor Necrosis Factor-alpha | 2015 |
Etanercept combined with systemic drugs or phototherapy for treatment of psoriasis.
Topics: Acitretin; Antirheumatic Agents; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Methotrexate; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; Coal Tar; Contraindications; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ultraviolet Therapy; Ustekinumab | 2015 |
Medical Treatments of Hidradenitis Suppurativa: More Options, Less Evidence.
Topics: Acitretin; Adrenal Cortex Hormones; Anti-Infective Agents; Cyclosporine; Dapsone; Dermatologic Agents; Gluconates; Hidradenitis Suppurativa; Hormones; Humans; Hypoglycemic Agents; Injections, Intralesional; Keratolytic Agents; Metformin; Ustekinumab | 2016 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
Advances in Psoriasis.
Topics: Acitretin; Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Humans; Interleukins; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Vitamin D | 2017 |
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Etanercept; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Psoriasis; Thalidomide; Ustekinumab | 2018 |
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Fumarates; Humans; Methotrexate; Multicenter Studies as Topic; Observational Studies as Topic; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Secukinumab (Cosentyx°) and plaque psoriasis.
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cyclosporine; Etanercept; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Failure; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2017 |
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Topics: Acitretin; Administration, Oral; Administration, Topical; Adult; Aged; Biological Products; Consensus; Cyclosporine; Dermatologic Agents; Disease Management; Expert Testimony; Female; Humans; Injections, Intralesional; Male; Methotrexate; Middle Aged; Nail Diseases; Practice Guidelines as Topic; Psoriasis; Recurrence; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
Topics: Acitretin; Antibodies, Monoclonal; Brazil; Clinical Decision-Making; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.
Topics: Acitretin; Adult; Cyclosporine; Humans; Methotrexate; Psoriasis; United States | 2021 |
Pustular psoriasis of pregnancy: Clinical and genetic characteristics in a series of eight patients and review of the literature.
Topics: Acitretin; Adult; CARD Signaling Adaptor Proteins; Cyclosporine; Female; Guanylate Cyclase; Humans; Infant; Infant, Newborn; Interleukins; Membrane Proteins; Pregnancy; Psoriasis; Retrospective Studies; Skin Diseases, Vesiculobullous; Steroids; Young Adult | 2022 |
An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations.
Topics: Acitretin; Chronic Disease; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Psoriasis | 2023 |
4 trial(s) available for acitretin and cyclosporine
| Article | Year |
|---|---|
The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Topics: Acitretin; Adult; Aged; Alefacept; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2006 |
A global approach to psoriatic patients through PASI score and Skindex-29.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Diagnostic Self Evaluation; Emotions; Etanercept; Female; Folic Acid; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interpersonal Relations; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
Topics: Acitretin; Adult; Biomarkers; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-2; Keratolytic Agents; Male; Middle Aged; Prognosis; Prospective Studies; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Topics: Acitretin; Cyclosporine; Hospitals; Humans; Methotrexate; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
66 other study(ies) available for acitretin and cyclosporine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol.
Topics: Acitretin; Calcitriol; Cyclosporine; Cytokines; Dexamethasone; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydrocortisone; Infant; Infant, Newborn; Interleukin-1; Interleukin-6; Male; Microcirculation; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 1992 |
Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Coal Tar; Cyclosporine; Humans; Interferon Type I; Interferon-alpha; Middle Aged; Pregnancy Proteins; Psoriasis; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 1994 |
Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering.
Topics: Acitretin; Chronic Disease; Cyclosporine; Female; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Recurrence; Remission Induction | 1994 |
The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin.
Topics: Acitretin; Aged; Antifungal Agents; Cyclosporine; Drug Therapy, Combination; Etretinate; Female; Humans; In Vitro Techniques; Isotretinoin; Male; Microsomes, Liver; Middle Aged; Naphthalenes; Psoriasis; Retinoids; Terbinafine | 1993 |
[Cyclosporine and Darier's disease].
Topics: Acitretin; Cyclosporine; Darier Disease; Etretinate; Humans; Male; Middle Aged; Treatment Failure | 1993 |
Plasma endothelin in psoriasis: possible relations to therapy and toxicity.
Topics: Acitretin; Cyclosporine; Endothelins; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Ranitidine | 1996 |
Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance.
Topics: Acitretin; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Neoplasms, Multiple Primary; Psoriasis; PUVA Therapy; Skin Neoplasms | 1997 |
Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis.
Topics: Acitretin; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Psoriasis; Sepsis; Staphylococcal Infections; Streptococcal Infections; Vancomycin | 1999 |
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin.
Topics: Acitretin; Alcoholism; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Leg; Male; Middle Aged; Psoriasis; PUVA Therapy; Skin Neoplasms; Ultraviolet Rays | 2003 |
Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.
Topics: Acitretin; Administration, Cutaneous; Adult; Cyclosporine; Dermatologic Agents; Humans; Keratolytic Agents; Male; Psoriasis; Skin; Treatment Outcome | 2004 |
Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing.
Topics: Acitretin; Cyclosporine; Female; Ficusin; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Photosensitizing Agents; Psoriasis; PUVA Therapy; Treatment Outcome | 2005 |
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Topics: Acitretin; Adult; Aged; Cyclosporine; Dermatologic Agents; Female; Ficusin; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Treatment Outcome; United States | 2005 |
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Topics: Acitretin; Adult; Costs and Cost Analysis; Cyclosporine; Dermatologic Agents; Female; Health Care Costs; Humans; Male; Managed Care Programs; Methotrexate; Middle Aged; New England; Phototherapy; Psoriasis; PUVA Therapy; Treatment Failure; United States | 2005 |
Aggressive undifferentiated squamous cell carcinoma in an immunosuppressed patient after kidney transplantation.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Oral; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Counseling; Cyclosporine; Follow-Up Studies; Humans; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Keratolytic Agents; Keratosis; Kidney Transplantation; Male; Middle Aged; Ointments; Skin; Skin Neoplasms; Sunscreening Agents; Time Factors | 2005 |
A novel treatment for recalcitrant benign familial pemphigus.
Topics: Acitretin; Bed Rest; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Middle Aged; Pemphigus, Benign Familial | 2007 |
Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Topics: Acitretin; Administration, Oral; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Keratolytic Agents; Male; Methotrexate; Patient Satisfaction; Psoriasis; PUVA Therapy; Surveys and Questionnaires; Treatment Outcome; Ultraviolet Therapy | 2007 |
Conventional therapies for psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Italy; Keratolytic Agents; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Generalized pustular psoriasis and cryptogenic organizing pneumonia.
Topics: Acitretin; Adult; Arthritis, Psoriatic; Cryptogenic Organizing Pneumonia; Cyclosporine; Dermatologic Agents; Etanercept; Fatal Outcome; Female; Humans; Immunoglobulin G; Protein C Inhibitor; Psoriasis; Receptors, Tumor Necrosis Factor | 2008 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |
Erythroderma in a patient taking acitretin for plaque psoriasis.
Topics: Acitretin; Cyclosporine; Dermatitis, Exfoliative; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2008 |
Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Case-Control Studies; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Female; Gene Frequency; Genotype; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Immune System; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Psoriasis; T-Lymphocytes; Young Adult | 2008 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Emollients; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Plant Extracts; Psoriasis; Receptors, Tumor Necrosis Factor; Salicylates; Steroids; Tars; Treatment Outcome; Ultraviolet Therapy | 2009 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Topics: Acitretin; Adalimumab; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tacrolimus; Treatment Outcome; Ustekinumab | 2011 |
[News on psoriasis from the 2010 Dermatology Days in Paris].
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cyclosporine; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Immunoglobulin G; Methotrexate; Practice Guidelines as Topic; Psoriasis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Treatment Outcome; Ustekinumab | 2011 |
Superimposed linear psoriasis: low effectiveness of biologic therapy.
Topics: Acitretin; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Biological Therapy; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Loss of Heterozygosity; Male; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor | 2011 |
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Melanoma; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2012 |
Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin.
Topics: Acitretin; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryotherapy; Cyclosporine; Dermatologic Agents; Eczema; Female; Humans; Keratoacanthoma; Keratolytic Agents; Keratosis, Actinic; Prurigo; Pruritus; Retrospective Studies | 2013 |
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Registries; Risk Assessment; Spain; Ustekinumab | 2015 |
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha | 2015 |
Acquired ichthyosis during acitretin therapy for psoriasis vulgaris.
Topics: Acitretin; Aged; Cyclosporine; Dermatologic Agents; Female; Humans; Ichthyosis; Keratolytic Agents; Psoriasis | 2016 |
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Young Adult | 2014 |
The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Topics: Acitretin; Adalimumab; Adult; Aged; Biological Factors; Cyclosporine; Dermatologic Agents; Drug Substitution; Etanercept; Female; Humans; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Psoriasis; Ustekinumab; Young Adult | 2015 |
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dapsone; Dermatologic Agents; Fumarates; Humans; Immunosuppressive Agents; Methotrexate; Practice Patterns, Physicians'; Psoriasis; United Kingdom | 2015 |
Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Germany; Humans; Infliximab; Isoxazoles; Keratolytic Agents; Leflunomide; Male; Methotrexate; Middle Aged; Prednisolone; Psoriasis; Retrospective Studies | 2015 |
Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Topics: Acitretin; Adalimumab; Attitude of Health Personnel; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Infliximab; Methotrexate; Perception; Practice Patterns, Physicians'; Psoriasis | 2015 |
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Biological Products; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Drug Prescriptions; Drug Therapy, Combination; Etanercept; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Ultraviolet Therapy; Ustekinumab; Young Adult | 2015 |
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Topics: Acitretin; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Etanercept; Fumarates; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Ustekinumab | 2015 |
Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Systemic treatments in childhood psoriasis: a French multicentre study on 154 children.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; France; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Treatment Outcome | 2016 |
Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Italy; Male; Methotrexate; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Treatment Outcome | 2016 |
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
Topics: Acitretin; Adalimumab; Cost-Benefit Analysis; Cyclosporine; Etanercept; Health Care Costs; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Models, Economic; Psoriasis; PUVA Therapy; Severity of Illness Index; Spain; Time Factors; Treatment Outcome; Ultraviolet Therapy; Ustekinumab | 2016 |
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Topics: Acitretin; Biological Factors; Cyclosporine; Dermatology; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Psoriasis; Societies, Medical; Switzerland; Thalidomide | 2016 |
Generalized pustular psoriasis treated with ustekinumab.
Topics: Acitretin; Adalimumab; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous; Treatment Outcome; Ustekinumab | 2016 |
Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.
Topics: Acitretin; Adolescent; Child; Cohort Studies; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Treatment Outcome | 2017 |
Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Topics: Acitretin; Adult; Biological Products; Body Mass Index; Comorbidity; Coronary Disease; Cyclosporine; Czech Republic; Dermatologic Agents; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Phototherapy; Prevalence; Psoriasis; Quality of Life; Registries; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index | 2017 |
Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
Topics: Acitretin; Acute Disease; Adolescent; Adult; Age of Onset; CARD Signaling Adaptor Proteins; Child; Child, Preschool; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Guanylate Cyclase; Humans; Interleukins; Keratolytic Agents; Malaysia; Male; Membrane Proteins; Pregnancy; Pregnancy Complications; Psoriasis; Respiratory Tract Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Steroids; Stress, Psychological; Tertiary Care Centers; Vaccination; Young Adult | 2017 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Topics: Acitretin; Adalimumab; Austria; Biological Products; Combined Modality Therapy; Cyclosporine; Czech Republic; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Humans; Infliximab; Israel; Italy; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Netherlands; Psoriasis; PUVA Therapy; Registries; Severity of Illness Index; Ustekinumab | 2018 |
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Age of Onset; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Spain; Ustekinumab | 2020 |
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Cyclosporine; Cytokine TWEAK; Dermatologic Agents; Etanercept; Female; Humans; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Treatment of pityriasis rubra pilaris: a case series of 28 patients.
Topics: Acitretin; Biological Products; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Pityriasis Rubra Pilaris; Retrospective Studies; Smoking; Ustekinumab | 2020 |
Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.
Topics: Acitretin; Biological Factors; Breast Feeding; Contraindications, Drug; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Psoriasis; Risk Factors; Ultraviolet Therapy | 2020 |
The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cardiovascular Diseases; Cyclosporine; Female; Humans; Incidence; Male; Methotrexate; Middle Aged; Phototherapy; Proportional Hazards Models; Psoriasis; Republic of Korea; Severity of Illness Index; Young Adult | 2021 |
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic.
Topics: Acitretin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Contraindications, Drug; COVID-19; Cyclosporine; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nails; Pandemics; Photopheresis; Psoriasis; Quality of Life; SARS-CoV-2; Severity of Illness Index; Ultraviolet Therapy | 2021 |
Conventional therapy in psoriasis. Lost in translation?
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Topics: Acitretin; Adjuvants, Immunologic; Biological Factors; Cohort Studies; Cyclosporine; Dermatologic Agents; Fumarates; Humans; Immunologic Factors; Male; Methotrexate; Prospective Studies; Psoriasis; Treatment Outcome | 2023 |
The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |